Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Biozone Pharmaceuticals, Inc. (BZNE) Merges With Cocrystal Discovery 0 comments
    Jan 6, 2014 10:36 AM | about stocks: COCP

    Biozone Pharmaceuticals has finalized its planned merger with Cocrystal Discovery, a private biotech company developing antiviral therapeutics for human diseases. Cocrystal has five therapeutic programs targeting the hepatitis C virus (HCV), influenza, the human rhinovirus (HRV), dengue, and the norovirus.

    The agreement names Dr. Gary Wilcox as chief executive officer and chairman of the board, and Dr. Roger Kornberg as chief scientist and a director of the combined entities.

    "We are keenly focused on bringing our small molecule inhibitors of the viral replication complex to market," Dr. Wilcox stated in the news release. "We believe in our ability to discover oral, once-a-day, broad-spectrum antiviral drug candidates targeting the polymerase enzyme of the Hepatitis C virus. This merger provides us even greater resources to help bring products to market and offers our shareholders an opportunity to realize significant value on their investment."

    Also joining the company are Dr. Phillip Frost, Dr. Sam Lee, Steven Rubin and Dr. Jane Hsiao.

    Dr. Frost stated, "We are excited about the team we have assembled with Dr. Wilcox's top-notch pedigree and successes in bringing products to market; I am confident in the future of this company. There are many compelling advantages to the technologies for small molecule inhibitors of the viral replication complex."

    Per the agreement, current shareholders of Biozone and Cocrystal will own approximately 40 percent and 60 percent of the combined company, respectively. The emerging entity plans to apply for a name and ticker change in the upcoming months to more accurately reflect the business moving forward.

    For more information, visit biozonelabs.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: COCP
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.